Our Commitment

Every cancer journey is a unique and personal experience for patients and very complex to be fully understood. We know that every cancer patient may also be a mother or father who want to see their children smile. A partner, a friend, a daughter, a son who long to kiss and hug their loved ones. It is with this knowledge that we conduct our science and cancer research to see another warm embrace, another smile or touch – we know how much they matter. A cancer diagnosis should not be the end of these essential moments. That is what we believe in and why we work relentlessly to answer patients’ needs in the best possible way.

TOGETHER FOR PATIENTS. TOGETHER FOR THOSE WHO STAND BESIDE THEM.

Our disease areas

With passion for true innovation we seek to transform standards in cancer patient care. All our scientific and research efforts seek to address areas of unmet medical need. By 2025 we want to become a global pharma innovator with competitive advantage in oncology and a trusted partner to the patient communities we serve.

World-Class Science Organization

We are committed to becoming a world-class science organization. Our team’s exceptional scientific attitude results in outstanding medicinal chemistry, antibody engineering and discovery biology.
 

Dynamic and Sustainable R&D Engine

The oncology portfolio of Daiichi Sankyo is powered by our research engine: Biologics, medicinal chemistry, modality, and other research laboratories in Japan

“3 and Alpha” R&D Strategy

Anchored by our DXd antibody drug conjugate (ADC) technology, our obligation is to harness the power of true innovation to discover and develop innovative first-in-class and best-in-class treatments that transform the standard of care for patients with cancer.
 

Enhanced Capabilities Through Collaboration

To complement and expand our premier cadre of internal scientists, we are collaborating with leading academic and business partners to leverage cutting-edge science in new treatment modalities, disease biology, diagnostics and pipeline prioritization.

References

1 As of March 31, 2022
https://www.daiichisankyo.com/files/investors/library/materials/2021/20210405_5th_MTP_E.pdf 
Source: Financial Highlights – Daiichi Sankyo https://www.daiichisankyo.com/investors/financial_highlights 

2  https://www.daiichisankyo.com/files/investors/library/quarterly_result/2020/pdf/FY2020_Q4_
Financial_Results_Presentation_EE.pdf

For legal reasons detailed information about prescription medicine may only be given to healthcare professionals.The agents discussed on the website are investigational and have not been approved by the EMA or any other regulatory agency worldwide as a treatment for any indication. Safety and efficacy have not been established.There is no guarantee that these compounds will become commercially available.

back to top

User login

Enter your username and password here in order to log in on the website